New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2013
11:17 EDTVRTXVertex Pharma May volatility elevated at 60
Vertex Pharma April call option implied volatility is at 52, May is at 60, July is at 54; above its 26-week average of 48 according to Track Data, suggesting larger price movement into upcoming VX-661/Kalydeco cystic fibrosis combo study.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
18:42 EDTVRTXOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTVRTXVertex expects FY14 revenues $525M-$535M, consensus $551.82M
Subscribe for More Information
16:18 EDTVRTXVertex reports Q3 adjusted EPS (37c), consensus (62c)
Subscribe for More Information
October 22, 2014
05:37 EDTVRTXVertex approval could add 500 more patients, says Piper Jaffray
Subscribe for More Information
October 21, 2014
16:49 EDTVRTXVertex: FDA Advisory Committee recommends approval of KALYDECO
Vertex Pharmaceuticals announced that the U.S. Food and Drug Administrationís Pulmonary Allergy Drugs Advisory Committee voted 13-2 to recommend approval of KALYDECO in people with cystic fibrosis ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory gene, which is the indication being reviewed by the FDA.
15:25 EDTVRTXPanel backs approval for Vertex CF drug in R117H mutation, Bloomberg says
Subscribe for More Information
15:18 EDTVRTXPanel votes Vertex CF drug safe, works for R117H mutation, Bloomberg reports
Subscribe for More Information
07:11 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committe to hold a meeting
Subscribe for More Information
October 17, 2014
10:27 EDTVRTXVertex FDA panel expected to be positive at Piper Jaffray
Subscribe for More Information
10:26 EDTVRTXFDA panel asked to consider benefit of Vertex drug in younger CF patients
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use